High prevalence of asymptomatic nosocomial candiduria due to Candida glabrata among hospitalized patients with heart failure: a matter of some concern?

Document Type : Original Articles

Authors

1 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

2 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

3 Department of Laboratory Medicine, Faculty of Allied Medical Sciences, Mazandaran University of medical science, Sari, Iran

10.18502/cmm.6.4.5327

Abstract

Background and Purpose: Heart failure is a leading cause of hospitalization, and asymptomatic candiduria is common in hospitalized patients with low morbidity. However, in most patients, it is resolved spontaneously on the removal of the catheter. Despite the publication of guidelines, there are still controversies over the diagnosis and management of candiduria. However, in hospitalized patients with heart failure, the decision to treat candiduria is especially important since the nosocomial infections are associated with an increase in morbidity, mortality, length of hospital stay, and healthcare costs. Some species of Candida, such as Candida glabrata, are increasingly resistant to the first-line and second-line antifungal medications. The present study aimed to investigate the incidence of asymptomatic Candida urinary tract infection due to C. glabrata and antifungal susceptibility of Candida isolates in hospitalized patients with heart failure.
Materials and Methods: In total, 305 hospitalized patients with heart failure were studied to identify asymptomatic nosocomial candiduria during 2016-17 in one private hospital in the north of Iran. The Sabouraud’s dextrose agar culture plates with a colony count of >104 colony-forming unit/ml of urine sample were considered as Candida urinary tract infection. Candida species were identified based on the morphology of CHROMagar Candida (manufactured by CHROMagar, France) and PCR-RFLP method with MspI restriction enzyme. Antifungal susceptibility testing of the isolates was performed using five mediations, including itraconazole, voriconazole, fluconazole, amphotericin B, and caspofungin by broth microdilution method according to CLSI M27-S4.
Results: In this study, the rate of asymptomatic Candida urinary tract infection was 18.8%, which was more common in people above 51 years old and females (70%). In addition to the urinary and intravascular catheter, the occurrence of candiduria in hospitalized patients had significant relationships with a history of surgical intervention, diastolic heart failure, and use of systemic antibiotics (P>0.05). Among Candida spp., non-albicans Candida species was the most common infectious agent (59.7%). Moreover, C. glabrata (n=27, 40.3%) (alone or with other species) and Candida albicans (n=27, 40.3%) were the most common agents isolated in Candida urinary tract infection. Based on the results of the in vitro susceptibility test, the C. glabrata isolates were 15%, 59%, 70%, 74%, and 85% susceptible to caspofungin, amphotericin B, itraconazole, voriconazole, and fluconazole, respectively.
Conclusion: According to the findings, there was a high prevalence of asymptomatic Candida urinary tract infection in hospitalized patients with heart failure. Besides, it was suggested that there was a shift towards non-albicans Candida, especially C. glabrata, in these patients. Therefore, asymptomatic candiduria in hospitalized patients with heart failure should be considered significant. Furthermore, the identification of Candida species along with antifungal susceptibility is essential and helps the clinicians to select the appropriate antifungal agent for better management of such cases.

Keywords

References

1 Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J. 2008; 155(2):200-7.
2. Vasiliadis I, Kolovou G, Kolovou V, Giannakopoulou V, Boutsikou M, Katsiki N, et al. Gene polymorphisms and thyroid function in patients with heart failure. Endocrine. 2014;45(1):46-54.
3. Dai S, Walsh P, Wielgosz A, Gurevich Y, Bancej C, Morrison H. Comorbidities and mortality associated with hospitalized heart failure in Canada. Can J Cardiol. 2012; 28(1):74-9.
4. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;8(8):e72476.
5. Montgomery K. Urinary tract infections and the heart. Acupuncture Today. 2009; 10(3):1-4.
6. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113(Suppl 1A):5S-13S.
7. Tannenbaum C, Johnell K. Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence. Drugs Aging. 2014;31(2):93-101.
8. Bronsema DA, Adams JR, Pallares R, Wenzel RP. Secular trends in rates and etiology of nosocomial urinary tract infections at a university hospital. J Urol. 1993;150(2 Pt 1):414-6.
9. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 2000; 21(8):510-5.
10. Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway, 2002 and 2003. J Hosp Infect. 2005; 60(1):40-5.
11. Ghiasian SA, Aghamirian MR, Eshghi GR. Nosocomial candiduria in critically III patients admitted to intensive care units in Qazvin, Iran. Avicenna J Clin Microb Infect. 2014; 1(2):21622.
12. Kauffman CA. Candiduria. Clin Infect Dis. 2005; 41(Suppl 6):S371-6.
13. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-35.
14. Ozhak-Baysan B, Ogunc D, Colak D, Ongut G, Donmez L, Vural T, et al. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria. Med Mycol. 2012; 50(5):529-32.
15. Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida urinary tract infections--diagnosis. Clin Infect Dis. 2011; 52(Suppl 6):S452-6.
16. Kauffman CA, Vasquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases Mycoses Study Group.Clin Infect Dis.2000; 30(1):14-8.
17. Falahati M, Farahyar S, Akhlaghi L, Mahmoudi S, Sabzian K, Yarahmadi M, et al. Characterization and identification of candiduria due to Candida species in diabetic patients. Curr Med Mycol. 2016;2(3):10-14.
18. Colombo AL, Garnica M, Aranha Camargo LF, Da Cunha CA, Bandeira AC, Borghi D, et al. Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. Med Mycol. 2013;51(1):38-44.
19. Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802-10.
20. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. InfectDrug Resist. 2017; 10:249-59.
21. Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. MedMycol. 2013; 51(6):657-63.
22. Abastabar M, Hosseinpoor S, Hedayati MT, Shokohi T, Valadan R, Mirhendi H, et al. Hyphal wall protein 1 gene: apotential marker for the identification of different Candida species and phylogenetic analysis. Curr Med Mycol. 2016; 2(4):1-8.
23. Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
24. Clinical Laboratory and Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing yeasts. CLSI document M27-S4. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
25. Santos ER, Dal Forno CF, Hernandez MG, Kubiça TF, Venturini TP, Chassot F, et al. Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. Rev Inst Med Trop Sao Paulo. 2014; 56(6):477-82.
26. Zarei Mahmoudabadi A, Keradmand AR, Enayatollahi N. Frequency of candiduria in inpatients and outpatients in department of urology, Golestan Hospital, Ahvaz, Iran. Iran J Kidney Dis. 2009; 3(2):114-5.
27. PakshirK, Moghadami M, Emami M, Kord Bacheh P. Prevalence and identification of etiological agents of funguria in Foley catheterized patients. Med Res Shiraz Univ Med Sci. 2004; 3:33-41.
28. Goyal RK, Sami H, Mishra V, Bareja R, Behara RN. Non-albicans candiduria: an emerging threat. J Appl Pharm Sci. 2016; 6(3):48-50.
29. Colonder R, Nuri Y, Chazan B, Raz R. Community-acquired and hospital acquired candiduira: comparison of prevalence and clinical characteristics. Eur J Clin Microbiol Infect Dis. 2008; 27(4):301-5.
30. GulerS, Ural O, Findik D, Arslan U. Risk factors for nosocomial candiduria. Saudi Med J. 2006; 27(11):1706-10.
31. García-Agudo L, Rodríguez-Iglesias M, Carranza-González R. Nosocomial Candiduria in the elderly: microbiological diagnosis. Mycopathologia. 2018; 183(3):591-6.
32. Kane LE, Muzevich KM. Micafungin in the treatment of candiduria: acase series. Med Mycol Case Rep. 2016; 11:5-8.
33. Talebitaher M, Naimi T, Shayanfar N, Nojomi M, Barati M. Nosocomial candiduria and risk factors in ICUs patients, Rasoul-e-Akram hospital, Tehran, Iran. Razi J Med Sci. 2016; 23(143):27-33.
34. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis. 1999; 29(4):926-8.
35. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010; 23(2):253-73.
36. Ullah A, Lopes MI, Brul S, Smits GJ. Intracellular pH homeostasis in Candida glabrata in infection-associated conditions. Microbiology. 2013; 159(Pt 4):803-13.
37. Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. infections in patients with diabetes mellitus. J Clin Med. 2019; 8(1):E76.
38. Kaur R, Dhakad MS, Goyal R, Kumar R. Emergence of non-albicans Candida species and antifungal resistance in intensive care unit patients. Asian Pac J Trop Biomed. 2016;6(5):455-60.
39. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012; 36(2):288-305.
40. Sousa IA, Braoios A, Santos TG, Lima JA, Costa RM. Candiduria in adults and children: prevalence and antifungal susceptibility in outpatient of Jataí-GO. J Bras Patol MedLab. 2014; 50(4):259-64.
41. Behzadi P, Behzadi E, Ranjbar R. Urinary tract infections and Candida albicans. Cent Eur J Urol. 2015; 68(1):96-101.
42. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015; 58(Suppl 2):2-13.
43. Rossoni RD, Barbosa JO, Vilela SF, dos Santos JD, de Barros PP, Prata MC,et al. Competitive interactions between C. albicans,C. glabrata and C. krusei during biofilm formation and development of experimental candidiasis. PLoS One. 2015; 10(7):e0131700.
44. Yang YL, Chu WL, Lin CC, Zhou ZL, Chen PN, Lo HJ, et al.Mixed yeast infections in Taiwan. Med Mycol. 2018;56(6):770-3.
45. Gharaghani M, Taghipour S, Halvaeezadeh M, Mahmoudabadi AZ. Candiduria; a review article with specific data from Iran. Turk J Urol. 2018; 44(6):445-52.
46. Zarei-Mahmoudabadi A, Zarrin M, Ghanatir F, Vazirianzadeh B.Candiduria in hospitalized patients in teaching hospitals of Ahvaz. Iran J Microbiol. 2012; 4(4):198-203.
47. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014; 10:95-105.
48. The global market for medical devices. Market Research Group, LLC. Kalorama Information. Available at: URL:https://www. kaloramainformation.com/medical-devices-market-c1126; 2018.
49. Jang AY, O’Brien C, Chung WJ, Oh PC, Yu J, Lee K, et al. Routine indwelling urethral catheterization in acute heart failure patients is associated with increased urinary tract complications without improved heart failure outcomes. Circ J. 2018; 82(6):1632-9.
50. Darouiche RO. Device-associated infections: a macro-problem that starts with micro-adherence. Clin Infect Dis. 2001; 33(9):1567-72.
51. Azad N, Kathiravelu A, Minoosepeher S, Hebert P, Fergusson D. Gender differences in the etiology of heart failure: asystematic review. J Geriatr Cardiol. 2011; 8(1):15-23.
52. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A-13A.
53. Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary heart disease. Am J Med. 2014;127(9):807-12.
54. Weinstein RA, Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis. 2001;32(11):1602-7.
55. Bandeira AC, Filho JM, de Almeida Ramos K. Reversible cardiomyopathy secondary to Amphotericin-B. Med Mycol Case Rep. 2016;13:19-21.
56. Bukhary ZA. Candiduria: a review of clinical significance and management. Saudi J Kidney Dis Transpl. 2008;19(3):350-60.
57. Mishra M, Agrawal S, Raut S, Kurhade AM, Powar RM. Profile of yeasts isolated from urinary tracts of catheterized patients. J Clin Diagn Res. 2014;8(2):44-6.
58. Esmailzadeh A, Zarrinfar H, Fata A, Sen T. High prevalence of
candiduria due to non-albicans Candida species among diabetic patients: amatter of concern? J Clin Lab Anal. 2018; 32(4):e22343.
59. Fazeli A, Kordbacheh P, Nazari A, Daie Ghazvini R, Mirhendi H, Safara M, et al. Candiduria in hospitalized patients and identification of isolated Candidaspecies by morphological and molecular methods in Ilam, Iran. Iran J Public Health. 2019;48(1):156-61.
60. Yismaw G, Asrat D, Woldeamanuel Y, Unakal C. Prevalence of candiduria in diabetic patients attending Gondar University Hospital, Gondar, Ethiopia. Iran J Kidney Dis. 2013; 7(2):102‐7.
61. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4(Suppl 1):19-26.
62. Aslani N, Shokohi T, Ataollahi MR, Ansari S, Gholampour Y, Khani Jeihooni A, et al. In vitro activity of four triazole antifungal drugs against clinically common and uncommon yeast species. Curr Med Mycol. 2019; 5(4):14-9.
63. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005; 49(2):668-79.
64. Amirrajab N, Badali H, Didehdar M, Afsarian MH, Mohammadi R, Lotfi N, et al. In vitro activities of six antifungal drugs againstCandida glabrataisolates: an emerging pathogen. Jundishapur J Microbiol. 2016; 9(5):e36638.
65. Bayraktar S, Duran N, Duran GG, Eryilmaz N, Aslan H, Önlen C, et al. Identification of medically important Candida species by polymerase chain reaction-restriction fragment length polymorphism analysis of the rDNA ITS1 and ITS2 regions. Indian J Med Microbiol. 2017; 35(4):535-42
66. Farasat A, Ghahri M, Mirhendi H, Beiraghi S. Identification of Candida species screened from catheter using patients with PCR-RFLP method. Eur J Exp Biol. 2012; 2(3):651-6.
67. Daef E, Moharram A, Eldin SS, Elsherbiny N, Mohammed M. Evaluation of chromogenic media and seminested PCR in the identification of Candida species. Braz J Microbiol. 2014; 45(1):255-62.
Current Medical Mycology
Volume 6, Issue 4
December 2020
Pages 1-8

Files

History

  • Receive Date: 28 May 2019
  • Accept Date: 28 September 2020
  • Publish Date: 01 December 2020

Share

How to cite

Statistics